

BEST AVAILABLE COPY*Lilly*

Fax

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

RECEIVED
CENTRAL FAX CENTER

Date: 3 March 2006

MAR 03 2006

To: A. Gupta
Company: USPTO
Fax: 571-273-8300
Technology Center 1600

From: Greg Cox
Fax: 317-276-5172
Phone: 317-277-2620
Total Pages: 5

Privileged and Confidential Communication

RE: : 09/400,802
Docket No. : X-11158
Group Art : 1654

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

Answers That Matter.

BEST AVAILABLE COPY**RECEIVED
CENTRAL FAX CENTER****MAR 03 2006****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

IANET FOWLER

Type or print name of person signing certification

Signature

Janet Fowler

Date

3-3-06**PATENT APPLICATION****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	: Suad Efendic) Confirmation No. 3827
Serial No.	: 09/400,802)
Filed	: September 22, 1999) Group Art Unit:1654
For	: Use of GLP-1 or Analogs in) Examiner: Anish Gupta
	Treatment of Stroke)
Docket No.	: X-11158)

REPLY UNDER 37 C.F.R. 1.111 & AMENDMENT UNDER 37 C.F.R. 1.121

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

Applicant submits a reply under 37 C.F.R. §1.111, and an amendment under 37 C.F.R. §1.121 to the outstanding Office Action issued for the above referenced case.

Applicant respectfully requests that the Examiner enter the following amendments that Applicant believes place the application in condition for allowance.

Claims begin on page 2 of this response.

Remarks begin on page 3 of this response.